e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

20th September 2019 by Louise Hudman

e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

This is a new guideline from NICE giving advice on ertugliflozin, published in April 2019. I am also doing a quick reminder about the other SGLT-2 inhibitors.

What is ertugliflozin?

It is another sodium-glucose co-transporter 2 (SGLT-2) inhibitor, like canagliflozin, dapagliflozin and empagliflozin.

It is thought to be as effective as the other SGLT-2 inhibitors, but it is cheaper.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"I don’t normally do this, but just to say that I thought your article at the front of the latest NASGP magazine about clinical errors was really excellent. Great, and very thoughtful writing. NASGP member."

‘Great, and very thoughtful writing’

‘Great, and very thoughtful writing’

See the full list of features within our NASGP membership plans

Membership